Muscle relaxation antagonist for reversing benzylisoquinoline muscle relaxants

By using the pharmaceutical composition prepared by Omeksone sodium, the adverse reactions such as heart rate instability and allergic reactions in the use of existing myoproliferative antagonists are solved, effectively antagonizing and heart rate protection of the residual effects of myoproliferative drugs, providing a safer and more effective clinical application solution.

CN119679816APending Publication Date: 2025-03-25HANGZHOU ADAMERCK PHARMLABS INC
0 Cites 0 Cited by

Patent Information

Application Number
CN202311194721.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-09-15
Publication Date
2025-03-25

AI Technical Summary

Technical Problem

Existing myoproliferative antagonists such as Neostigmine and Susquitoglucose sodium have heart rate instability, allergic reactions and other adverse reactions during use, which is difficult to meet the clinical need for safe and effective antagonist residual effects of myoproliferative drugs.

Method used

Omeksone sodium is used as a small molecule drug to prepare a pharmaceutical composition of Omeksone sodium to reverse neuromuscular block induced by benzylisoquinoline muscle relaxants and improve adverse reactions in the antagonistic process of muscle relaxation.

Benefits of technology

Omexon sodium significantly shortened the recovery time of residual muscle relaxation in the cisatracuron-induced muscle relaxation model, and its safety is better than neostigmine in heart rate protection, reducing the occurrence of postoperative adverse reactions.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a muscle relaxation antagonist for reversing benzylisoquinoline muscle relaxants, particularly provides a preparation method and application of a safer and more effective muscle relaxation antagonist preparation for reversing benzylisoquinoline muscle relaxants, and more particularly provides a preparation method and application of the muscle relaxation antagonist preparation for reversing benzylisoquinoline muscle relaxants. The invention provides omekasone sodium as a substitute for neostigmine for reversing muscle relaxation of a benzylisoquinoline muscle relaxation drug cisatracurium besylate. In the process of remnant neuromuscular block after muscle relaxation induced by a muscle relaxation agent cisatracurium, the omekasone sodium can replace neostigmine, and the omekasone sodium is remarkably superior to neostigmine in the aspects of heart rate maintenance and the like under the condition that the antagonistic drug effect is maintained to be equivalent. The invention also provides the Omexone sodium and a compound pharmaceutical preparation thereof, the Omexone sodium is prepared into freeze-dried powder injection or injection, and the Omexone sodium is suitable for being applied to preparation of antagonistic muscle relaxation drugs.
Need to check novelty before this filing date? Find Prior Art